Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

109.86 +2.92 (+2.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

September 30, 2026

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O...

Via StockStory

Topics Artificial Intelligence

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

September 24, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge...

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock to Target This Week and 2 We Question

September 22, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗

September 09, 2026

Via Chartmill

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗

September 02, 2026

This biotech innovator could be in only the early chapters of its success story.

Via The Motley Fool

Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗

August 28, 2026

Via Chartmill

Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗

August 20, 2026

Via Chartmill

1 Mid-Cap Stock on Our Watchlist and 2 We Avoid

August 31, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Topics Fraud

3 Market-Beating Stocks for Long-Term Investors

August 28, 2026

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 We Avoid

August 27, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

Via StockStory

Topics Economy

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges

August 24, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗

June 25, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗

June 03, 2026

Via Chartmill

Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Revenue jumped 48% to $481 million on record royalty growth.

Via The Motley Fool

Topics Earnings

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

August 13, 2026

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance ...

Via StockStory

Topics Earnings Intellectual Property

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

August 07, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on ...

Via StockStory

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

August 07, 2026

What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company ...

Via StockStory

Topics Artificial Intelligence

1 Profitable Stock to Research Further and 2 We Ignore

August 07, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Halozyme Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from...

Via MarketBeat

Topics Earnings

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

August 06, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales...

Via StockStory

What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

August 04, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after the bell. Here’s what to ...

Via StockStory

3 Growth Stocks Set to Flourish

August 03, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

July 24, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Topics Energy

1 Value Stock Worth Investigating and 2 Facing Headwinds

July 15, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

Via StockStory

2 Reasons to Like HALO and 1 to Stay Skeptical

July 10, 2026

Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 ha...

Via StockStory

Topics Stocks

1 Surging Stock for Long-Term Investors and 2 We Brush Off

July 01, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

2 Profitable Stocks Worth Your Attention and 1 We Question

June 18, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Topics Credit Cards

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

June 03, 2026

What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst re...

Via StockStory

Topics Economy

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 18, 2026

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp...

Via StockStory

Topics Earnings

Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

May 13, 2026

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Via StockStory

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.